Biomarker testing informs individualized diagnosis and treatment of low-to-intermediate risk AML
Alexander E. Perl, MD, MS. According to Alexander E. Perl, MD, MS, the acute myeloid leukemia (AML) treatment landscape includes emerging therapies and diagnostic strategies that simultaneously address previously unmet needs and raise further questions regarding the classification of diseases. In 2022, the European LeukemiaNet (ELN) updated its AML recommendations based on a growing understanding …